文献速递淋巴瘤

维布妥昔单抗联合来那度胺治疗复发或难治性弥漫大B细胞淋巴瘤的1期/剂量扩展试验

Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma.
PubMed 文献 · Blood · 2022-01-01

该1期/剂量扩展试验评估维布妥昔单抗(BV)联合来那度胺(Len)治疗复发/难治性弥漫大B细胞淋巴瘤(DLBCL),37例患者每21天接受BV,Len持续给药最多16周期。最大耐受剂量为BV 1.2 mg/kg联合Len 20 mg/d,总缓解率57%(95%CI 39.6-72.5),完全缓解率35%(95%CI 20.7-52.6),中位缓解持续时间13.1个月,中位无进展生存期10.2个月,中位总生存期14.3个月。CD30+患者缓解率最高(73%),缓解率不因细胞起源不同而异(P=.96)。

要点

  • BV/Len联合方案最大耐受剂量为BV 1.2 mg/kg联合Len 20 mg/d。
  • 总缓解率57%,完全缓解率35%,中位无进展生存期10.2个月。
  • CD30+患者缓解率最高(73%),缓解率不因细胞起源不同而异。

核心结论

  • BV/Len联合方案是复发/难治性DLBCL患者的潜在治疗选择,该联合方案正在一项3期研究(NCT04404283)中进一步探索。

研究设计与样本

  • 1期/剂量扩展试验,纳入37例复发/难治性DLBCL患者,BV每21天给药,Len持续给药最多16周期。

主要发现

  • 最大耐受剂量为BV 1.2 mg/kg联合Len 20 mg/d。
  • 总缓解率为57%(95%CI 39.6-72.5),完全缓解率为35%(95%CI 20.7-52.6)。
  • 中位缓解持续时间为13.1个月,中位无进展生存期为10.2个月(95%CI 5.5-13.7),中位总生存期为14.3个月(95%CI 10.2-35.6)。
  • CD30+ DLBCL患者缓解率最高(73%),缓解率不因细胞起源不同而异(P=.96)。
  • 多数患者因中性粒细胞减少需要粒细胞集落刺激因子支持。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

New therapies are needed for patients with relapsed/refractory (rel/ref) diffuse large B-cell lymphoma (DLBCL) who do not benefit from or are ineligible for stem cell transplant and chimeric antigen receptor therapy. The CD30-targeted, antibody-drug conjugate brentuximab vedotin (BV) and the immunomodulator lenalidomide (Len) have demonstrated promising activity as single agents in this population. We report the results of a phase 1/dose expansion trial evaluating the combination of BV/Len in rel/ref DLBCL. Thirty-seven patients received BV every 21 days, with Len administered continuously for a maximum of 16 cycles. The maximum tolerated dose of the combination was 1.2 mg/kg BV with 20 mg/d Len. BV/Len was well tolerated with a toxicity profile consistent with their use as single agents. Most patients required granulocyte colony-stimulating factor support because of neutropenia. The overall response rate was 57% (95% CI, 39.6-72.5), complete response rate, 35% (95% CI, 20.7-52.6); median duration of response, 13.1 months; median progression-free survival, 10.2 months (95% CI, 5.5-13.7); and median overall survival, 14.3 months (95% CI, 10.2-35.6). Response rates were highest in patients with CD30+ DLBCL (73%), but they did not differ according to cell of origin (P = .96). NK cell expansion and phenotypic changes in CD8+ T-cell subsets in nonresponders were identified by mass cytometry. BV/Len represents a potential treatment option for patients with rel/ref DLBCL. This combination is being further explored in a phase 3 study (registered on https://clinicaltrials.org as NCT04404283). This trial was registered on https://clinicaltrials.gov as NCT02086604.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Ward JP, Berrien-Elliott MM, Gomez F, et al. Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma. Blood. 2022. PMID: 34780623. doi:10.1182/blood.2021011894

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。